ALT-803, an IL-15 superagonist, in combination withnivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. (Lancet Oncology, 2018)
IL-2 and Beyond in Cancer Immunotherapy (Journal ofInterferon and Cytokine Research, 2018)
Enhanced Lymphodepletion Is Insufficient to ReplaceExogenous IL2 or IL15 Therapy in Augmenting the Efficacy of AdoptivelyTransferred Effector CD8+ T Cells. (Cancer Research, 2018)
IL-2Rα mediates temporal regulation of IL-2 signaling andenhances immunotherapy (Science Translational Medicine, 2015)